AbbVie Takes $744M R&D Charge, Trims Q1 Earnings Guidance by $0.41 Per Share
AbbVie (ABBV) disclosed Thursday that first-quarter 2026 earnings will take a $0.41 per share hit from $744 million in acquired intellectual property and milestone expenses, according to an 8-K filing with the SEC.
Key Numbers
The pharmaceutical giant's Q1 2026 adjusted earnings per share guidance now stands at $2.56-$2.60, down from what would have been $2.97-$3.01 without the charge. The $744 million pre-tax expense relates to acquired in-process research and development (IPR&D) and milestone payments from licensing agreements and collaborations executed during the quarter.
Despite the quarterly impact, AbbVie maintained its full-year 2026 adjusted EPS guidance at $13.96-$14.16, inclusive of the first-quarter charge. The company's original February guidance had explicitly excluded potential IPR&D expenses due to their unpredictable nature.
For context, AbbVie reported $15.78 billion in revenue for Q3 2025, with net income of $190 million or $0.10 per share. The full fiscal year 2025 saw revenue of $61.16 billion and net income of $4.23 billion, translating to $2.36 per share.
What Management Said
While CEO commentary was not included in this preliminary filing, the company emphasized that first-quarter results remain subject to financial statement closing procedures and that final figures could differ from these estimates.
AbbVie management noted in the filing that they typically do not forecast IPR&D and milestone expenses "due to uncertainty of the future occurrence and timing of these transactions." This language suggests the $744 million charge represents opportunistic deals or strategic partnerships that emerged during the quarter rather than planned expenditures.
The filing, signed by Executive Vice President and CFO Scott T. Reents, maintains standard forward-looking statement disclaimers citing potential risks from intellectual property challenges, competition, R&D difficulties, adverse litigation, regulatory changes, and global macroeconomic factors.
What to Watch
The $744 million R&D charge signals AbbVie continues actively investing in its pipeline through external partnerships and asset acquisitions, critical for replacing revenue from its blockbuster immunology drug Humira, which lost U.S. exclusivity in 2023. While such charges are non-recurring by nature, they reflect the company's ongoing strategy to supplement internal R&D with external innovation.
Investors should monitor whether additional IPR&D charges materialize in subsequent quarters, as these could further pressure near-term earnings. The company's ability to maintain its full-year guidance despite absorbing nearly three-quarters of a billion dollars in unplanned expenses suggests underlying business performance remains solid.
When AbbVie reports complete Q1 results, likely in late April or early May, key metrics to watch include Humira's rate of decline in the U.S. market, growth trajectories for newer immunology drugs Skyrizi and Rinvoq, and any updates on the company's oncology and neuroscience pipelines. Management commentary on the specific assets or partnerships behind the $744 million charge will provide insight into AbbVie's strategic priorities.
The maintenance of full-year guidance implies management expects operational performance in the remaining quarters to offset the Q1 charge, suggesting either conservative initial guidance or confidence in accelerating growth through 2026.
*Source: AbbVie Inc. Form 8-K filed with the Securities and Exchange Commission on April 3, 2026*
*StockCliff Research*